HERA W10 Diagnostic Ultrasound System; HERA W9 Diagnostic Ultrasound System

The Samsung Medison HERA W10 and HERA W9 are advanced, general-purpose diagnostic ultrasound systems designed to enhance medical imaging across diverse clinical applications through the integration of AI-based tools and remote viewing capabilities. Their development involved comprehensive non-clinical testing to demonstrate substantial equivalence, safety, and effectiveness, leading to FDA authorization for market release.

The U.S. Food & Drug Administration (FDA) has granted marketing authorization to Samsung Medison Co., Ltd. for its HERA W10 and HERA W9 Diagnostic Ultrasound Systems as of November 27, 2024. This authorization confirms the devices' substantial equivalence to already legally marketed devices, allowing them to be used for general diagnostic applications under standard regulatory controls including annual registration, adherence to manufacturing practices, and truthful labeling. These mobile, software-controlled ultrasound systems are designed for a broad spectrum of clinical applications such as fetal, abdominal, cardiac, and musculoskeletal studies, offering various operational modes. Key technological advancements include AI-based tools like BiometryAssist, ViewAssist, and Heart Assist, alongside remote diagnostic image viewing via SonoSync, all of which were supported by comprehensive non-clinical testing covering acoustic output, safety, and imaging performance to ensure their safety and effectiveness.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific improvements or unique capabilities do the AI-based tools (BiometryAssist, ViewAssist, Heart Assist) offer over existing ultrasound systems?; How does the SonoSync feature ensure data security and privacy during remote diagnostic image viewing?; What are the long-term clinical outcomes or diagnostic accuracy improvements observed in real-world settings after the adoption of HERA W10/W9 systems?; Are there any specific patient populations or clinical scenarios where the HERA W10/W9 systems demonstrate superior performance compared to other high-end ultrasound devices?; What is the training requirement or learning curve for clinicians to effectively utilize the advanced features and AI tools of these systems?